The Effect of Solifenacin on Post Void Dribbling in Women

University of Wisconsin, Madison118 enrolled

Overview

This is a double-blind, randomized, controlled, parallel design (n=140) study with the purpose of measuring the efficacy of Solifenacin 5mg in the treatment of women with Post Void Dribbling.

This investigation will have a double-blind, randomized, and controlled, parallel design with the % reduction in post void dribbling episodes (events) as the primary endpoint. Secondary endpoints will include: 1. The % of patients with at least a 50% reduction in post void dribbling episodes. 2. Patient's perspective of the impact of their disease, which will be captured using the Pelvic Floor Distress Inventory, and another questionnaire that asks about urinary symptoms and quality of life. We will compare Solifenacin 5 mg to placebo. 140 subjects will be enrolled, with 70 subjects in each arm. The treatment group will receive 5mg of Solifenacin daily for 12 weeks. Astellas Pharma will be supplying both drug and placebo, they will be prepackaged and numbered. The Pharmaceutical Research Center will randomly assign subjects into the treatment vs. placebo group blinding both the subjects and investigators

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

118

Conditions

Post-micturition Incontinence Incontinence

Interventions

solifenacinDRUG

patient will receive solifenacin 5mg daily or placebo daily

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 89 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Women between the ages of 18 and 89 2. Incontinence in the form of post void dribbling that occurs at least twice weekly. Exclusion Criteria: 1. Severe renal or hepatic disease. 2. Active urinary tract infection. 3. Glaucoma. 4. Stress incontinence as the only incontinence symptom 5. Urge incontinence as the only incontinence symptom 6. Chronic severe constipation. 7. History of bladder cancer. 8. Known or suspected hypersensitivity to anticholinergics. 9. Any clinical condition that would not allow safe completion of the study. 10. Pregnancy or lactation, intention to become pregnant during the study, or use of an unreliable birth control method in women of childbearing potential. Reliable forms of contraception include: permanent sterilization of either partner, hormonal contraception (oral contraceptive, Nuva ring, contraceptive patch, depoprovera, implants), intrauterine device (IUD), and condoms. Abstinence is considered a reliable form of contraception, but abstinent subjects will be informed that they need to use condoms or other form of birth control mentioned above if they become sexually active during the study. 11. Presently on systemic anti-cholinergic therapy or who have been on therapy within the last 4 weeks. Anti-cholinergic drugs include; darifenacin, fesoterodine, hyoscyamine, oxybutynin, solifenacin, tolterodine, and trospium. 12. Solid forms of potassium supplementation, as this presents an increased risk of GI side effects.

Locations (1)

UW Hospital and Clinics

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

The Percent Reduction in Post Void Dribbling Episodes (Events)

Time frame: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of weeks 10 through 12

Secondary Outcomes

the Percent of Patients With at Least 50% Reduction in Post Void Dribbling Episodes

Time frame: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of weeks 10 through 12

Change in Patients Perspective of the Impact of Their Disease, Captured Using the Pelvic Floor Distress Inventory (Urinary Questions)

The difference between baseline and follow up (last 20 days on drug) scores was the recorded measure. The larger the negative # the greater the effect. The survey was divided into 3 sections, each section worth 100 points. Total scores could range from 0 to 300 (0 no disease, 300 severe disease).

Time frame: outcome measures will be assessed at week 0 (baseline), and compared to an average measure of the last 20 days on placebo or treatment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.